Just because a patient is diagnosed with cancer doesn’t mean that there isn’t hope. Personalizing oncology could change the face of cancer treatment.
Every patient’s tumor is unique. This is why two patients with the same cancer often respond differently to identical treatments. The Champions TumorGraftTM is a powerful tool in personalizing treatment, helping patients identify which treatments should work for their individual tumor. With this data in hand, patients and physicians can make more informed, personalized treatment decisions for each patient’s cancer.
Champions TumorGrafts are living near-replicas of the patient’s tumor, growing outside of the patient’s body. We do this by collecting live tumor and its supporting tissue following a patient’s surgery or biopsy. When the live tumor arrives in our labs, we grow and multiply the tumor, creating a personalized Champions TumorGraftTM. Our scientists work with patients and their physicians to identify the treatments they would like to test on the TumorGraft. Our labs then test and measure the effectiveness of each of these therapies on the patient’s personal Champions TumorGraftTM. This data has proved invaluable for many patients, identifying unlikely therapies and producing real results.
The case study below is based on a single patient’s experience and is presented for illustrative purposes only. Champions TumorGraftTM testing services provide information to assist physicians in selecting a course of treatment. We do not sell any product intended for the diagnosis, cure, mitigation, treatment, or prevention of any disease or condition and cannot make any claim or guarantee regarding the effectiveness of any course of therapy. Each patient’s experience is different and we cannot guarantee similar results for other patients.
Sarah (name changed to protect patient confidentiality) was 44 years old and had metastatic colorectal cancer when she came to Champions. She had already received multiple rounds of chemotherapy and had progressive disease. In an effort to identify the likely performance of her next course of treatment, Sarah sent her live tumor to be grown in a Champions TumorGraftTM.
Sarah’s physician and the Champions scientists designed a TumorGraft drug study, testing a number of different drug options as both single agent and in combination therapies. Sarah’s TumorGraft identified a likely strong response to a single agent therapy. Sarah’s cancer responded to this single agent therapy with 60% regression for 50 months.
In total, Sarah’s was treated for over 56 months with two courses of therapy guided by Champions TumorGraft information.
Champions TumorGrafts helped Sarah test her treatment options. Each patient’s outcome will vary based on the effectiveness and performance of the drugs they chose to test.
Champions TumorGraftsTM were developed by Dr. David Sidransky, a world renowned oncologist and researcher. For the past six years Champions has offered TumorGrafts to patients and physicians across the US, UK and Israel.
We have successfully developed Champions TumorGraftsTM for almost all major cancer types including colon, breast, ovarian, lung, sarcoma, pancreatic, and germ cell cancers. Our patients range from small children to active adults to the elderly.
Champions is proud to bring this exciting technology to patients and physicians, offering hope for life through smarter, personalized cancer care.
Like this post? Subscribe to my RSS feed and get loads more!